Using AI-Powered Models and Drug-Response Data, Predictive Oncology (NASDAQ: POAI) Holds Strong Position in Burgeoning Precision Oncology Industry
Precision oncology leverages the profile of genetic mutations in patients for the purpose of delivering precision drug-based cancer therapy Precision oncology industry forecast to be worth 99.72 billion by 2027 according to recent report POAI applies AI to proprietary data trove, aiding oncologists in personalizing cancer therapies in addition to collaborating with pharmaceutical companies for drug discovery Precision oncology is driven by the profile of genetic mutations in tumors that give practitioners required information to target therapies based off the specific mutations in the patient’s tumor. According to a recent research report, the industry is predicted to be worth 99.72…